COVID-19
Conditions
Interventions
None listed
Sponsors
Nagasaki University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients who visited Nagasaki University Hospital or collaborating hospitals for COVID-19 and were diagnosed with mild COVID-19 between the date of research approval by the director of the institution and December 31, 2022. (2) Patients who were followed up without treatment in an outpatient clinic after the diagnosis of mild COVID-19 (3) Patients who were prescribed antiviral drugs as outpatients after the diagnosis of mild COVID-19 (4) Age: 18 years and older (5) Patients who are able to respond to questionnaires via the Internet (6) Patients who have received a full explanation of their participation in this study, and who have given their voluntary consent based on a good understanding of the study
Exclusion criteria
Exclusion criteria: (1) Patients diagnosed with moderate or severe COVID-19 at the time of first visit (2) Patients diagnosed with COVID-19 during hospitalization (3) Patients with COVID-19 who were started on antiviral drugs during hospitalization (4) Other patients deemed inappropriate as research subjects by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Development of COVID-19 persistent symptoms at 12 weeks after first visit | — |
Secondary
| Measure | Time frame |
|---|---|
| Development of COVID-19 persistent symptoms at 28 days, 24 weeks, 36 weeks, and 48 weeks after first visit Comparison of patient background (age, days of disease onset, number of SARS-Cov-2 vaccinations, risk of COVID-19 severity) in each group Search for predictive factors for the development of COVID-19 persistent symptoms using blood samples Hospitalization rate within 28 days of first visit | — |
Countries
Japan
Contacts
Public ContactTakahiro Takazono
Nagasaki University Graduate school of Biomedical Sciensse department of infectious diseases
Outcome results
None listed